Answers are grounded in this paper and cite their sources.
Review explores how pioglitazone improves cardiovascular outcomes in type 2 diabetes, suggesting effective treatment strategies.
Antidiabetic medications that improve glycemic control as well as cardiovascular outcomes will be the mainstay of treatment for type 2 diabetes moving forward. This article reviews the beneficial effects of the thiazolidinedione pioglitazone of ameliorating hyperglycemia and improving cardiovascular risk factors. While the newer sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist drug classes have confirmed cardiovascular benefits, pioglitazone also has been shown to reduce major adverse cardiovascular events, in both people with type 2 diabetes and nondiabetic subjects with insulin resistance. Adverse effects associated with pioglitazone can be mitigated by its use at a lower dose and in combination with antidiabetic agents from other drug classes.
No takes yet. Share an insight, caveat, or question.
Tripathy et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: